Vaxcyte, Inc. — Director's Dealing 2022

Oct 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-10-24

Reporting Person: Lukatch Heath (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-24	Common Stock	M	3015	$16.00	Acquired	6140	Direct
2022-10-24	Common Stock	S	3015	$35.11	Disposed	3125	Direct
2022-10-26	Common Stock	M	4000	$16.00	Acquired	7125	Direct
2022-10-26	Common Stock	S	4000	$38.25	Disposed	3125	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-24	Stock Option (right to buy)	$16.00	D	3015	Disposed	2030-06-10	Common Stock (3015)	Direct
2022-10-26	Stock Option (right to buy)	$16.00	D	4000	Disposed	2030-06-10	Common Stock (4000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.